Global Neurodegenerative Diseases Therapeutics Market 2022 by Company, Regions, Type and Application, Forecast to 2028
Page: 102
Published Date: 30 Apr 2022
Category: Medical Care
PDF Download
Get FREE Sample
Customize Request
-
Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Description
The Neurodegenerative Diseases Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Neurodegenerative Diseases Therapeutics market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. Child accounting for % of the Neurodegenerative Diseases Therapeutics global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Multiple Sclerosis Therapeutics segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Neurodegenerative Diseases Therapeutics include AB Science SA, AbbVie Inc., Acadia Pharmaceuticals Inc., Biogen Inc., and F. Hoffmann La Roche Ltd., etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Neurodegenerative Diseases Therapeutics market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Multiple Sclerosis Therapeutics
Alzheimer's Disease Therapeutics
Parkinson's Disease Therapeutics
Parkinson's Disease Therapeutics
Others
Market segment by Application, can be divided into
Child
Aldult
Market segment by players, this report covers
AB Science SA
AbbVie Inc.
Acadia Pharmaceuticals Inc.
Biogen Inc.
F. Hoffmann La Roche Ltd.
H Lundbeck AS
Mitsubishi Chemical Holdings Corp.
Novartis AG
Sanofi
Teva Pharmaceutical Industries Ltd
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Neurodegenerative Diseases Therapeutics product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Neurodegenerative Diseases Therapeutics, with revenue, gross margin and global market share of Neurodegenerative Diseases Therapeutics from 2019 to 2022.
Chapter 3, the Neurodegenerative Diseases Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Neurodegenerative Diseases Therapeutics market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Neurodegenerative Diseases Therapeutics research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 Product Overview and Scope of Neurodegenerative Diseases Therapeutics
1.2 Classification of Neurodegenerative Diseases Therapeutics by Type
1.2.1 Overview: Global Neurodegenerative Diseases Therapeutics Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Type in 2021
1.2.3 Multiple Sclerosis Therapeutics
1.2.4 Alzheimer's Disease Therapeutics
1.2.5 Parkinson's Disease Therapeutics
1.2.6 Parkinson's Disease Therapeutics
1.2.7 Others
1.3 Global Neurodegenerative Diseases Therapeutics Market by Application
1.3.1 Overview: Global Neurodegenerative Diseases Therapeutics Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Child
1.3.3 Aldult
1.4 Global Neurodegenerative Diseases Therapeutics Market Size & Forecast
1.5 Global Neurodegenerative Diseases Therapeutics Market Size and Forecast by Region
1.5.1 Global Neurodegenerative Diseases Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Neurodegenerative Diseases Therapeutics Market Size by Region, (2017-2022)
1.5.3 North America Neurodegenerative Diseases Therapeutics Market Size and Prospect (2017-2028)
1.5.4 Europe Neurodegenerative Diseases Therapeutics Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size and Prospect (2017-2028)
1.5.6 South America Neurodegenerative Diseases Therapeutics Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Neurodegenerative Diseases Therapeutics Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Neurodegenerative Diseases Therapeutics Market Drivers
1.6.2 Neurodegenerative Diseases Therapeutics Market Restraints
1.6.3 Neurodegenerative Diseases Therapeutics Trends Analysis
2.1 AB Science SA
2.1.1 AB Science SA Details
2.1.2 AB Science SA Major Business
2.1.3 AB Science SA Neurodegenerative Diseases Therapeutics Product and Solutions
2.1.4 AB Science SA Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 AB Science SA Recent Developments and Future Plans
2.2 AbbVie Inc.
2.2.1 AbbVie Inc. Details
2.2.2 AbbVie Inc. Major Business
2.2.3 AbbVie Inc. Neurodegenerative Diseases Therapeutics Product and Solutions
2.2.4 AbbVie Inc. Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 AbbVie Inc. Recent Developments and Future Plans
2.3 Acadia Pharmaceuticals Inc.
2.3.1 Acadia Pharmaceuticals Inc. Details
2.3.2 Acadia Pharmaceuticals Inc. Major Business
2.3.3 Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Product and Solutions
2.3.4 Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Acadia Pharmaceuticals Inc. Recent Developments and Future Plans
2.4 Biogen Inc.
2.4.1 Biogen Inc. Details
2.4.2 Biogen Inc. Major Business
2.4.3 Biogen Inc. Neurodegenerative Diseases Therapeutics Product and Solutions
2.4.4 Biogen Inc. Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Biogen Inc. Recent Developments and Future Plans
2.5 F. Hoffmann La Roche Ltd.
2.5.1 F. Hoffmann La Roche Ltd. Details
2.5.2 F. Hoffmann La Roche Ltd. Major Business
2.5.3 F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Product and Solutions
2.5.4 F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 F. Hoffmann La Roche Ltd. Recent Developments and Future Plans
2.6 H Lundbeck AS
2.6.1 H Lundbeck AS Details
2.6.2 H Lundbeck AS Major Business
2.6.3 H Lundbeck AS Neurodegenerative Diseases Therapeutics Product and Solutions
2.6.4 H Lundbeck AS Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 H Lundbeck AS Recent Developments and Future Plans
2.7 Mitsubishi Chemical Holdings Corp.
2.7.1 Mitsubishi Chemical Holdings Corp. Details
2.7.2 Mitsubishi Chemical Holdings Corp. Major Business
2.7.3 Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Product and Solutions
2.7.4 Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Mitsubishi Chemical Holdings Corp. Recent Developments and Future Plans
2.8 Novartis AG
2.8.1 Novartis AG Details
2.8.2 Novartis AG Major Business
2.8.3 Novartis AG Neurodegenerative Diseases Therapeutics Product and Solutions
2.8.4 Novartis AG Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Novartis AG Recent Developments and Future Plans
2.9 Sanofi
2.9.1 Sanofi Details
2.9.2 Sanofi Major Business
2.9.3 Sanofi Neurodegenerative Diseases Therapeutics Product and Solutions
2.9.4 Sanofi Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Sanofi Recent Developments and Future Plans
2.10 Teva Pharmaceutical Industries Ltd
2.10.1 Teva Pharmaceutical Industries Ltd Details
2.10.2 Teva Pharmaceutical Industries Ltd Major Business
2.10.3 Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Product and Solutions
2.10.4 Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Teva Pharmaceutical Industries Ltd Recent Developments and Future Plans
3.1 Global Neurodegenerative Diseases Therapeutics Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Neurodegenerative Diseases Therapeutics Players Market Share in 2021
3.2.2 Top 10 Neurodegenerative Diseases Therapeutics Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Neurodegenerative Diseases Therapeutics Players Head Office, Products and Services Provided
3.4 Neurodegenerative Diseases Therapeutics Mergers & Acquisitions
3.5 Neurodegenerative Diseases Therapeutics New Entrants and Expansion Plans
4.1 Global Neurodegenerative Diseases Therapeutics Revenue and Market Share by Type (2017-2022)
4.2 Global Neurodegenerative Diseases Therapeutics Market Forecast by Type (2023-2028)
5.1 Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Application (2017-2022)
5.2 Global Neurodegenerative Diseases Therapeutics Market Forecast by Application (2023-2028)
6.1 North America Neurodegenerative Diseases Therapeutics Revenue by Type (2017-2028)
6.2 North America Neurodegenerative Diseases Therapeutics Revenue by Application (2017-2028)
6.3 North America Neurodegenerative Diseases Therapeutics Market Size by Country
6.3.1 North America Neurodegenerative Diseases Therapeutics Revenue by Country (2017-2028)
6.3.2 United States Neurodegenerative Diseases Therapeutics Market Size and Forecast (2017-2028)
6.3.3 Canada Neurodegenerative Diseases Therapeutics Market Size and Forecast (2017-2028)
6.3.4 Mexico Neurodegenerative Diseases Therapeutics Market Size and Forecast (2017-2028)
7.1 Europe Neurodegenerative Diseases Therapeutics Revenue by Type (2017-2028)
7.2 Europe Neurodegenerative Diseases Therapeutics Revenue by Application (2017-2028)
7.3 Europe Neurodegenerative Diseases Therapeutics Market Size by Country
7.3.1 Europe Neurodegenerative Diseases Therapeutics Revenue by Country (2017-2028)
7.3.2 Germany Neurodegenerative Diseases Therapeutics Market Size and Forecast (2017-2028)
7.3.3 France Neurodegenerative Diseases Therapeutics Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Neurodegenerative Diseases Therapeutics Market Size and Forecast (2017-2028)
7.3.5 Russia Neurodegenerative Diseases Therapeutics Market Size and Forecast (2017-2028)
7.3.6 Italy Neurodegenerative Diseases Therapeutics Market Size and Forecast (2017-2028)
8.1 Asia-Pacific Neurodegenerative Diseases Therapeutics Revenue by Type (2017-2028)
8.2 Asia-Pacific Neurodegenerative Diseases Therapeutics Revenue by Application (2017-2028)
8.3 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Region
8.3.1 Asia-Pacific Neurodegenerative Diseases Therapeutics Revenue by Region (2017-2028)
8.3.2 China Neurodegenerative Diseases Therapeutics Market Size and Forecast (2017-2028)
8.3.3 Japan Neurodegenerative Diseases Therapeutics Market Size and Forecast (2017-2028)
8.3.4 South Korea Neurodegenerative Diseases Therapeutics Market Size and Forecast (2017-2028)
8.3.5 India Neurodegenerative Diseases Therapeutics Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Neurodegenerative Diseases Therapeutics Market Size and Forecast (2017-2028)
8.3.7 Australia Neurodegenerative Diseases Therapeutics Market Size and Forecast (2017-2028)
9.1 South America Neurodegenerative Diseases Therapeutics Revenue by Type (2017-2028)
9.2 South America Neurodegenerative Diseases Therapeutics Revenue by Application (2017-2028)
9.3 South America Neurodegenerative Diseases Therapeutics Market Size by Country
9.3.1 South America Neurodegenerative Diseases Therapeutics Revenue by Country (2017-2028)
9.3.2 Brazil Neurodegenerative Diseases Therapeutics Market Size and Forecast (2017-2028)
9.3.3 Argentina Neurodegenerative Diseases Therapeutics Market Size and Forecast (2017-2028)
10.1 Middle East & Africa Neurodegenerative Diseases Therapeutics Revenue by Type (2017-2028)
10.2 Middle East & Africa Neurodegenerative Diseases Therapeutics Revenue by Application (2017-2028)
10.3 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Country
10.3.1 Middle East & Africa Neurodegenerative Diseases Therapeutics Revenue by Country (2017-2028)
10.3.2 Turkey Neurodegenerative Diseases Therapeutics Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Neurodegenerative Diseases Therapeutics Market Size and Forecast (2017-2028)
10.3.4 UAE Neurodegenerative Diseases Therapeutics Market Size and Forecast (2017-2028)
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table of Figures
List of Tables
Table 1. Global Neurodegenerative Diseases Therapeutics Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Neurodegenerative Diseases Therapeutics Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Neurodegenerative Diseases Therapeutics Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Neurodegenerative Diseases Therapeutics Revenue (USD Million) by Region (2017-2022)
Table 5. Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Region (2023-2028)
Table 6. AB Science SA Corporate Information, Head Office, and Major Competitors
Table 7. AB Science SA Major Business
Table 8. AB Science SA Neurodegenerative Diseases Therapeutics Product and Solutions
Table 9. AB Science SA Neurodegenerative Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. AbbVie Inc. Corporate Information, Head Office, and Major Competitors
Table 11. AbbVie Inc. Major Business
Table 12. AbbVie Inc. Neurodegenerative Diseases Therapeutics Product and Solutions
Table 13. AbbVie Inc. Neurodegenerative Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Acadia Pharmaceuticals Inc. Corporate Information, Head Office, and Major Competitors
Table 15. Acadia Pharmaceuticals Inc. Major Business
Table 16. Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Product and Solutions
Table 17. Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Biogen Inc. Corporate Information, Head Office, and Major Competitors
Table 19. Biogen Inc. Major Business
Table 20. Biogen Inc. Neurodegenerative Diseases Therapeutics Product and Solutions
Table 21. Biogen Inc. Neurodegenerative Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. F. Hoffmann La Roche Ltd. Corporate Information, Head Office, and Major Competitors
Table 23. F. Hoffmann La Roche Ltd. Major Business
Table 24. F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Product and Solutions
Table 25. F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. H Lundbeck AS Corporate Information, Head Office, and Major Competitors
Table 27. H Lundbeck AS Major Business
Table 28. H Lundbeck AS Neurodegenerative Diseases Therapeutics Product and Solutions
Table 29. H Lundbeck AS Neurodegenerative Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Mitsubishi Chemical Holdings Corp. Corporate Information, Head Office, and Major Competitors
Table 31. Mitsubishi Chemical Holdings Corp. Major Business
Table 32. Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Product and Solutions
Table 33. Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Novartis AG Corporate Information, Head Office, and Major Competitors
Table 35. Novartis AG Major Business
Table 36. Novartis AG Neurodegenerative Diseases Therapeutics Product and Solutions
Table 37. Novartis AG Neurodegenerative Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Sanofi Corporate Information, Head Office, and Major Competitors
Table 39. Sanofi Major Business
Table 40. Sanofi Neurodegenerative Diseases Therapeutics Product and Solutions
Table 41. Sanofi Neurodegenerative Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Teva Pharmaceutical Industries Ltd Corporate Information, Head Office, and Major Competitors
Table 43. Teva Pharmaceutical Industries Ltd Major Business
Table 44. Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Product and Solutions
Table 45. Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. Global Neurodegenerative Diseases Therapeutics Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 47. Global Neurodegenerative Diseases Therapeutics Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 48. Breakdown of Neurodegenerative Diseases Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 49. Neurodegenerative Diseases Therapeutics Players Head Office, Products and Services Provided
Table 50. Neurodegenerative Diseases Therapeutics Mergers & Acquisitions in the Past Five Years
Table 51. Neurodegenerative Diseases Therapeutics New Entrants and Expansion Plans
Table 52. Global Neurodegenerative Diseases Therapeutics Revenue (USD Million) by Type (2017-2022)
Table 53. Global Neurodegenerative Diseases Therapeutics Revenue Share by Type (2017-2022)
Table 54. Global Neurodegenerative Diseases Therapeutics Revenue Forecast by Type (2023-2028)
Table 55. Global Neurodegenerative Diseases Therapeutics Revenue by Application (2017-2022)
Table 56. Global Neurodegenerative Diseases Therapeutics Revenue Forecast by Application (2023-2028)
Table 57. North America Neurodegenerative Diseases Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 58. North America Neurodegenerative Diseases Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 59. North America Neurodegenerative Diseases Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 60. North America Neurodegenerative Diseases Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 61. North America Neurodegenerative Diseases Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 62. North America Neurodegenerative Diseases Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 63. Europe Neurodegenerative Diseases Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 64. Europe Neurodegenerative Diseases Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 65. Europe Neurodegenerative Diseases Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 66. Europe Neurodegenerative Diseases Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 67. Europe Neurodegenerative Diseases Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 68. Europe Neurodegenerative Diseases Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 69. Asia-Pacific Neurodegenerative Diseases Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 70. Asia-Pacific Neurodegenerative Diseases Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 71. Asia-Pacific Neurodegenerative Diseases Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 72. Asia-Pacific Neurodegenerative Diseases Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 73. Asia-Pacific Neurodegenerative Diseases Therapeutics Revenue by Region (2017-2022) & (USD Million)
Table 74. Asia-Pacific Neurodegenerative Diseases Therapeutics Revenue by Region (2023-2028) & (USD Million)
Table 75. South America Neurodegenerative Diseases Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 76. South America Neurodegenerative Diseases Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 77. South America Neurodegenerative Diseases Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 78. South America Neurodegenerative Diseases Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 79. South America Neurodegenerative Diseases Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 80. South America Neurodegenerative Diseases Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 81. Middle East & Africa Neurodegenerative Diseases Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 82. Middle East & Africa Neurodegenerative Diseases Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 83. Middle East & Africa Neurodegenerative Diseases Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 84. Middle East & Africa Neurodegenerative Diseases Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 85. Middle East & Africa Neurodegenerative Diseases Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 86. Middle East & Africa Neurodegenerative Diseases Therapeutics Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Neurodegenerative Diseases Therapeutics Picture
Figure 2. Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Type in 2021
Figure 3. Multiple Sclerosis Therapeutics
Figure 4. Alzheimer's Disease Therapeutics
Figure 5. Parkinson's Disease Therapeutics
Figure 6. Parkinson's Disease Therapeutics
Figure 7. Others
Figure 8. Neurodegenerative Diseases Therapeutics Revenue Market Share by Application in 2021
Figure 9. Child Picture
Figure 10. Aldult Picture
Figure 11. Global Neurodegenerative Diseases Therapeutics Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 12. Global Neurodegenerative Diseases Therapeutics Revenue and Forecast (2017-2028) & (USD Million)
Figure 13. Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Region (2017-2028)
Figure 14. Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Region in 2021
Figure 15. North America Neurodegenerative Diseases Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 16. Europe Neurodegenerative Diseases Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. Asia-Pacific Neurodegenerative Diseases Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. South America Neurodegenerative Diseases Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. Middle East and Africa Neurodegenerative Diseases Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. Neurodegenerative Diseases Therapeutics Market Drivers
Figure 21. Neurodegenerative Diseases Therapeutics Market Restraints
Figure 22. Neurodegenerative Diseases Therapeutics Market Trends
Figure 23. AB Science SA Recent Developments and Future Plans
Figure 24. AbbVie Inc. Recent Developments and Future Plans
Figure 25. Acadia Pharmaceuticals Inc. Recent Developments and Future Plans
Figure 26. Biogen Inc. Recent Developments and Future Plans
Figure 27. F. Hoffmann La Roche Ltd. Recent Developments and Future Plans
Figure 28. H Lundbeck AS Recent Developments and Future Plans
Figure 29. Mitsubishi Chemical Holdings Corp. Recent Developments and Future Plans
Figure 30. Novartis AG Recent Developments and Future Plans
Figure 31. Sanofi Recent Developments and Future Plans
Figure 32. Teva Pharmaceutical Industries Ltd Recent Developments and Future Plans
Figure 33. Global Neurodegenerative Diseases Therapeutics Revenue Share by Players in 2021
Figure 34. Neurodegenerative Diseases Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 35. Global Top 3 Players Neurodegenerative Diseases Therapeutics Revenue Market Share in 2021
Figure 36. Global Top 10 Players Neurodegenerative Diseases Therapeutics Revenue Market Share in 2021
Figure 37. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 38. Global Neurodegenerative Diseases Therapeutics Revenue Share by Type in 2021
Figure 39. Global Neurodegenerative Diseases Therapeutics Market Share Forecast by Type (2023-2028)
Figure 40. Global Neurodegenerative Diseases Therapeutics Revenue Share by Application in 2021
Figure 41. Global Neurodegenerative Diseases Therapeutics Market Share Forecast by Application (2023-2028)
Figure 42. North America Neurodegenerative Diseases Therapeutics Sales Market Share by Type (2017-2028)
Figure 43. North America Neurodegenerative Diseases Therapeutics Sales Market Share by Application (2017-2028)
Figure 44. North America Neurodegenerative Diseases Therapeutics Revenue Market Share by Country (2017-2028)
Figure 45. United States Neurodegenerative Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 46. Canada Neurodegenerative Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. Mexico Neurodegenerative Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. Europe Neurodegenerative Diseases Therapeutics Sales Market Share by Type (2017-2028)
Figure 49. Europe Neurodegenerative Diseases Therapeutics Sales Market Share by Application (2017-2028)
Figure 50. Europe Neurodegenerative Diseases Therapeutics Revenue Market Share by Country (2017-2028)
Figure 51. Germany Neurodegenerative Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. France Neurodegenerative Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. United Kingdom Neurodegenerative Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Russia Neurodegenerative Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Italy Neurodegenerative Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Asia-Pacific Neurodegenerative Diseases Therapeutics Sales Market Share by Type (2017-2028)
Figure 57. Asia-Pacific Neurodegenerative Diseases Therapeutics Sales Market Share by Application (2017-2028)
Figure 58. Asia-Pacific Neurodegenerative Diseases Therapeutics Revenue Market Share by Region (2017-2028)
Figure 59. China Neurodegenerative Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Japan Neurodegenerative Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. South Korea Neurodegenerative Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. India Neurodegenerative Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Southeast Asia Neurodegenerative Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Australia Neurodegenerative Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. South America Neurodegenerative Diseases Therapeutics Sales Market Share by Type (2017-2028)
Figure 66. South America Neurodegenerative Diseases Therapeutics Sales Market Share by Application (2017-2028)
Figure 67. South America Neurodegenerative Diseases Therapeutics Revenue Market Share by Country (2017-2028)
Figure 68. Brazil Neurodegenerative Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Argentina Neurodegenerative Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Middle East and Africa Neurodegenerative Diseases Therapeutics Sales Market Share by Type (2017-2028)
Figure 71. Middle East and Africa Neurodegenerative Diseases Therapeutics Sales Market Share by Application (2017-2028)
Figure 72. Middle East and Africa Neurodegenerative Diseases Therapeutics Revenue Market Share by Country (2017-2028)
Figure 73. Turkey Neurodegenerative Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Saudi Arabia Neurodegenerative Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. UAE Neurodegenerative Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Methodology
Figure 77. Research Process and Data Source
Research Methodology
Client Requirements
Review and analyze client requirements
Discussion of all the project requirements and queries
Flexibility Check
Project Feasibility Analysis
Finalizing tentative research programme
Structuring project proposal with scope, timeline, and costs
Analyzing Market Dynamics
Determination of key drivers, restraints, challenge, and opportunity
Identifies market needs and trends
Market Size Estimation & Forecast
Estimation of historical data based on secondary and primary data
Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)
Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies
Consideration of geography, region-specific product/service demand for region segments
Consideration of product utilization rates, product demand outlook for segments by application or end-user.
Data Source
Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports,
paid database, press releases, blogs, newsletters,and GIR repositories.
Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts
to verify insights.
Validation
and
triangulation of
secondary and primary source.
Collection of data
Cumulating and collating the essential qualitative and quantitative data
Generation of report in client requested format by research analysts
Reviews by expert analysts
Final quality check
Clarifying queries
Receiving feedback
Ensuring satisfaction
01 Identification of data
This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
-
02 Evaluation of Market Dynamic
This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
-
03 Collection of Data
This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
-
04 Collaboration of Data
This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis
This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.
Companies Mentioned
AB Science SA AbbVie Inc. Acadia Pharmaceuticals Inc. Biogen Inc. F. Hoffmann La Roche Ltd. H Lundbeck AS Mitsubishi Chemical Holdings Corp. Novartis AG Sanofi Teva Pharmaceutical Industries Ltd
Related Reports
05 Feb 2023
Medical Care
Purchase Options
Add To Cart
Buy Now
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>
